Gilead Sciences (GILD) said post included inappropriate characterization of the study - STAT, citing Spokesperson
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
WHO China Data Likely to Drive View that Gilead (GILD) Remdesivir Isn't Working in Severe Patients - Raymond James
April 23, 2020 2:00 PM EDTRaymond James analyst Steven Seedhouse weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
"GILD's immediate response seems to be that the Chinese data do not enable statistically meaningful... More
Gilead Sciences (GILD) China Trial Results 'In Line with our Expectations' - RBC
April 23, 2020 1:40 PM EDTRBC Capital analyst Brian Abrahams weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
"If this is ultimately confirmed, this would be completely in line with our... More
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM EDTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
Skorney commented, "This afternoon, an abstract leaked indicating that Gilead's remdesivir failed to provide a benefit... More
